The effect of food on the pharmacokinetics, tolerability and pharmacodynamics of BNC210 in healthy male volunteers.

Trial Profile

The effect of food on the pharmacokinetics, tolerability and pharmacodynamics of BNC210 in healthy male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 08 Jul 2011 Actual initiation date (5 May 2010) added as reported by Australian New Zealand Clinical Trials Registry.
    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12610000442000).
    • 21 Jun 2010 Status changed from planning to completed, according to a Bionomics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top